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We would like to present an unusual case of hypercalcae-
mia in a 19 year-old patient with cystic fibrosis (CF). He was
homozygous for the ΔF508 mutation and retained excellent
lung function with a FEV1 of 4.47 L (105% predicted) and a
FVC of 5.84 (130% predicted). Sputum cultures were
persistently negative for Pseudomonas aeruginosa. The
patient was pancreatic insufficient and had been prescribed
Creon 10000 and vitamin A, D and E supplements.
Unfortunately concordance with treatment and out-patient
attendance was poor.
At annual assessment the patient's serum vitamin D level
was noted to be 32 nmol L−1 (Sufficiency N75 nmol L−1)
while vitamin A and serum adjusted calcium levels were
normal. C-Reactive protein was normal at annual assess-
ment. Poor concordance was addressed by the attending
physician and he was started on two tablets of Calcichew D3
Forte (Ca2+ 12.6 mmol, colecalciferol 10 μg/tablet) and
continued on 3 capsules of Vitamin A+D (vitamin A
4000 IU/capsule; vitamin D 10 μg/capsule).
One month after starting Calcichew D3 Forte, a routine
blood test revealed asymptomatic hypercalcaemia with
serum adjusted calcium level of 2.77 mmol L−1 (Normal
range 2.20–2.60 mmol L−1).
The patient was advised to stop taking Calcichew D3
Forte due to concern that the increased calcium intake could
have precipitated hypercalcaemia. His concordance with oral
medication had also improved.
Shortly after stopping the Calcichew D3 Forte he
developed an acute pulmonary exacerbation requiring
intravenous antibiotics. The adjusted serum calcium levels
were repeated and remained elevated both during and for over
2 months following his admission for intravenous antibiotic
treatment.
Further investigations for parathyroid hormone (PTH),
serum angiotensin converting enzyme, thyroid stimulating
hormone and renal function were normal. Alkaline phospha-
tase was slightly elevated at 380 IU L−1 (Normal range 220–
300 IU L−1). This result was not different from the patient’s
previous results and was felt to be a reflection of longstanding1569-1993/$ - see front matter © 2007 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2006.12.004CF related liver disease. Fasting vitamin A was elevated at
3.77 μmol L−1 (Normal range 1.05–3.39 μmol L−1) while
fasting vitamin D levels remained suboptimal at 23.6 nmol
L−1.
In view of the laboratory investigations a diagnosis of
hypercalcaemia secondary to hypervitaminosis Awas made.
The patient's vitamin A+D supplements were reduced to one
capsule and he was recommenced on 2 capsules of Calcichew
D3 Forte. Vitamin A levels were in the normal range at
2.28 μmol L−1 6months after adjustment of his vitaminA+D
supplements and the hypercalcaemia has not reoccurred.
Hypercalcaemia related to hypervitaminosis A is rare but
is recognised in patients undergoing haemodialysis [1],
receiving enteral feeding [2], consuming large amount of
vitamin A supplements [3], prescribed retinol based acne
treatment [4,5] and has been described once previously in a
patient with CF [6]. Most cases of hypercalcaemia are usually
due to chronic ingestion, however hypercalcaemia has been
reported after 11 days of ingestion of high amounts of vitamin
A [7]. While vitamin A induced hypercalcaemia usually
resolves after reducing or stopping vitamin A supplementa-
tion, steroid therapy can be helpful in refractory cases [5].
The mechanism by which excess vitamin A induces
hypercalcaemia is not well understood and is not thought to
be due to the production of excess PTH [8]. The bones of rats
fed large quantities of vitamin A show evidence of increased
osteoclastic activity and bone resorption [9,10]. More recent
work has shown evidence that vitamin A induces loss of bone
mass via a mechanism that is independent of the vitamin D
endocrine system [11].
The presence of hypervitaminosisA has important potential
ramifications for individuals with CF as it is associated with
osteoporosis and liver disease. There are several reasons why
our young man may have developed hypervitaminosis A.
Firstly his concordance had improved significantly and he
reported taking regular vitamin A supplements. He had also
started taking nutritionally complete sip feeds which provided
an additional 2544 IU vitamin A and 13.8 mmol calcium per
day. Our patient may have been protected to some extent from
hypercalcaemia due to the presence of concurrent hypovita-
minosis D. It is important to remember that plasma vitamin Aed by Elsevier B.V. All rights reserved.
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can be influenced by ongoing inflammation, retinol binding
protein levels, plasma zinc and liver disease.
Active inflammation can cause a reduction in serum
vitamin A levels; therefore vitamin A monitoring should be
carried out at a time of clinical stability and/or alongside a
marker of inflammation. Measurement of retinol binding
protein and plasma zinc may aid the interpretation of plasma
vitamin A level.
This case highlights the importance of regular vitamin A
monitoring in patients with CF and the complex interaction
between vitamin A, vitamin D and calcium metabolism.
Vitamin A deficiency is common in pancreatic insufficient
patients who do not receive appropriate supplementation, but
hypervitaminosis A can occur and is potentially associated
with important complications.
References
[1] Davis DR. Hypervitaminosis A, hypercalcemia and hemodialysis.
West J Med 1983;139(2):231.
[2] Bhalla K, Ennis DM, Ennis ED. Hypercalcemia caused by iatrogenic
hypervitaminosis A. J Am Diet Assoc 2005;105(1):119–21.
[3] Baxi SC, Dailey III GE. Hypervitaminosis A. A cause of hypercal-
cemia. West J Med 1982;137(5):429–31.
[4] Sharieff GQ, Hanten K. Pseudotumor cerebri and hypercalcemia
resulting from vitamin A toxicity. Ann Emerg Med 1996;27
(4):518–21.[5] Bergman SM, O'Mailia J, Krane NK, Wallin JD. Vitamin-A-induced
hypercalcemia: response to corticosteroids. Nephron 1988;50
(4):362–4.
[6] Eid NS, Shoemaker LR, Samiec TD. Vitamin A in cystic fibrosis: case
report and review of the literature. J Pediatr Gastroenterol Nutr
1990;10(2):265–9.
[7] Bush ME, Dahms BB. Fatal hypervitaminosis A in a neonate. Arch
Pathol Lab Med 1984;108(10):838–42.
[8] Katz CM, Tzagournis M. Chronic adult hypervitaminosis A with
hypercalcemia. Metabolism 1972;21(12):1171–6.
[9] Hough S, Avioli LV, Muir H, Gelderblom D, Jenkins G, Kurasi H, et al.
Effects of hypervitaminosis A on the bone and mineral metabolism of
the rat. Endocrinology 1988;122(6):2933–9.
[10] Frankel TL, Seshadri MS, McDowall DB, Cornish CJ. Hypervitamin-
osis A and calcium-regulating hormones in the rat. J Nutr 1986;116
(4):578–87.
[11] Rohde CM, DeLuca H. Bone resorption activity of all-trans retinoic
acid is independent of vitamin D in rats. J Nutr 2003;133(3):777–83.
I.J. Clifton*
A.M. Morton
D.G. Peckham
S.P. Conway
Regional Adult Cystic Fibrosis Unit,
Seacroft Hospital, Leeds, UK
E-mail address: i.j.clifton@btinternet.com.
⁎Corresponding author.
29 June 2006
